ARS Pharmaceuticals (SPRY) Net Cash Flow (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Net Cash Flow data on file, last reported at -$17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 55.17% year-over-year to -$17.0 million; the trailing twelve-month figure through Mar 2026 stood at -$15.5 million (up 3.71% YoY), and the FY2025 full-year result was -$9.5 million, up 52.86% from the prior year.
• Net Cash Flow advanced to -$17.0 million in Q1 2026, from -$18.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $173.2 million in Q4 2022 to a low of -$122.7 million in Q1 2023.
• A 5-year average of -$2.1 million and a median of -$7.6 million in 2022 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 508.91% in 2023, while the deepest fall reached 1461.7% in 2023.
• Tracing SPRY's Net Cash Flow over 5 years: stood at $173.2 million in 2022, then plunged by 93.97% to $10.4 million in 2023, then rose by 6.91% to $11.2 million in 2024, then slumped by 263.44% to -$18.2 million in 2025, then advanced by 6.82% to -$17.0 million in 2026.
• Business Quant data shows SPRY's Net Cash Flow at -$17.0 million in Q1 2026, -$18.2 million in Q4 2025, and $8.0 million in Q3 2025.